Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsJun Gong, Ravi Salgia|Journal for ImmunoTherapy of Cancer|2018Cited by 1.3k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerRazelle Kurzrock, Ravi Salgia, Lei Ye et al.|Journal of Clinical Oncology|2011Cited by 551
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer CellsPankaj Garg, Sharad S. Singhal, Jyoti Malhotra et al.|Cancers|2024Cited by 268
c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and InvasionKenjiro Sawada, Ernst Lengyel, A. Reza Radjabi et al.|Cancer Research|2007Cited by 260
c-Met Is a Potentially New Therapeutic Target for Treatment of Human MelanomaNeelu Puri, Ravi Salgia|Clinical Cancer Research|2007Cited by 154